Speeding Access to Precision Oncology Drugs: How Are We Doing With Biomarker-Driven Drug Approvals?
J Natl Compr Canc Netw
.
2020 Jan;18(1):113-114.
doi: 10.6004/jnccn.2019.7523.
Author
Tianhong Li
PMID:
31910383
DOI:
10.6004/jnccn.2019.7523
No abstract available
MeSH terms
Biomarkers
Drug Approval
Humans
Neoplasms*
Pharmaceutical Preparations*
Precision Medicine
United States
United States Food and Drug Administration
Substances
Biomarkers
Pharmaceutical Preparations